Difference between revisions of "Team:Cardiff Wales/practisepage1"

Line 115: Line 115:
 
     <body>
 
     <body>
 
<h1><center>Cardiff 2017 Project Brief</center></h1>
 
<h1><center>Cardiff 2017 Project Brief</center></h1>
−
 
+
<center>
 
     <section>
 
     <section>
 
     <img src="http://img.medscapestatic.com/pi/meds/ckb/78/31078.png" />
 
     <img src="http://img.medscapestatic.com/pi/meds/ckb/78/31078.png" />
 
</section>
 
</section>
−
 
+
</center>
 
<div class="clear"></div>
 
<div class="clear"></div>
 
<div class="column half_size" >
 
<div class="column half_size" >

Revision as of 09:30, 29 June 2017

Project

Cardiff 2017 Project Brief

Creating a thyroid stimulating hormone antagonist by removing essential N-linked glycosylation groups

The objective of this project was to take the native version of thyroid stimulating hormone (TSH, AKA. Thyrotropin) which activates a cascade in the thyroid gland to produce thyroid hormones thyroxine (T4) and tri-iodotyrosine (T3).

By changing the amino acid sequence of the native TSH protein, we can disable the gland-activating effects of TSH, whilst still allowing TSH to bind to the gland. The engineered version still binds to the thyroid gland but does not activate it. Thus, it competitively inhibits the native TSH, and is potentially a therapeutic treatment for hyperthyroidism.